Subramani Yamini, Rajarathinam Manikandan, Dabirzadeh Anita, Tawfic Qutaiba, Krause Sarah, Avci Yasin, Nagappa Mahesh
Anesthesiology and Perioperative Medicine, London Health Sciences Centre, Western University, London, Canada.
Anesthesiology and Perioperative Medicine, London Health Sciences Centre, Western University, London, CAN.
Cureus. 2024 Mar 27;16(3):e57057. doi: 10.7759/cureus.57057. eCollection 2024 Mar.
This systematic review was conducted to evaluate the optimal weight scalar to dose sugammadex in a morbidly obese (MO) patient population (BMI≥40 kg/m). The primary outcome was recovery time from moderate neuromuscular blockade (NMB) or deep NMB. Secondary outcomes included time to extubation and incidence of postoperative residual curarization (PORC). Eight randomized controlled trials (RCTs) involving 645 participants were included. The different dose scalars included were total body weight (TBW), ideal body weight (IBW), 20% corrected body weight (CBW) and 40% CBW). A dose of 2 mg/kg of sugammadex based on 40% CBW and a 4 mg/kg dose of sugammadex based on 40% CBW provide a reliable and timely reversal of moderate and deep NMB respectively in the MO patients.
本系统评价旨在评估病态肥胖(MO)患者群体(BMI≥40 kg/m²)中舒更葡糖钠给药的最佳体重标量。主要结局是中度神经肌肉阻滞(NMB)或深度NMB后的恢复时间。次要结局包括拔管时间和术后残余肌松(PORC)发生率。纳入了八项随机对照试验(RCT),涉及645名参与者。纳入的不同剂量标量包括总体重(TBW)、理想体重(IBW)、20%校正体重(CBW)和40%CBW。基于40%CBW的2 mg/kg舒更葡糖钠剂量和基于40%CBW的4 mg/kg舒更葡糖钠剂量分别能可靠且及时地逆转MO患者的中度和深度NMB。